Evaluation of a Simple Pharmacokinetic Tool (myPKFiT™) to Guide Personalized Factor VIII Dosing in Patients With Hemophilia
NCT02750085 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 39
Last updated 2020-05-15
Summary
This is an investigator-initiated, industry-funded, multi-centre, international study that will be carried out prospectively at hemophilia treatment centres across Canada, the Czech Republic and Australia with SickKids as the coordinating site. The study will use a central laboratory not directly affiliated with any of the participating sites. Enrollment target is 50 participants, both adult and pediatric with severe hemophilia A receiving Advate, who will each complete a 2-point and 6-point pharmacokinetic (PK) sampling. The main aim is to compare the results of a 2 sample PK using clinically practical time points and myPKFiT™ (a web-based, population PK Bayesian tool) to a 6 sample population PK to determine whether the results obtained are in good agreement.
Conditions
Sponsors & Collaborators
-
St. Paul's Hospital
collaborator UNKNOWN -
Montreal Children's Hospital of the MUHC
collaborator OTHER -
Queen's University
collaborator OTHER -
University Hospital, Motol
collaborator OTHER -
The University Hospital Brno
collaborator UNKNOWN -
Royal Children's Hospital
collaborator OTHER -
Sydney Children's Hospitals Network
collaborator OTHER -
Royal Prince Alfred Hospital, Sydney, Australia
collaborator OTHER -
Victor Blanchette
lead OTHER
Principal Investigators
-
Victor S Blanchette, MD · The Hospital for Sick Children
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-04-30
- Primary Completion
- 2019-01-31
- Completion
- 2020-12-31
More Related Trials
-
Personalized Prediction of Tolerance and Immunogenicity in Hemophilia
NCT01626105 ·Status: UNKNOWN
-
Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®
NCT03006965 ·Status: COMPLETED
-
Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101
NCT00189982 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia
NCT00178607 ·Status: COMPLETED
-
PF-06741086 Multiple Dose Study in Severe Hemophilia
NCT02974855 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)
NCT03587116 ·Status: COMPLETED ·Phase: PHASE3
-
PK Driven Prophylaxis for Hemophilia A
NCT02634424 ·Status: TERMINATED ·Phase: NA
-
Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A
NCT02256917 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A
NCT02093897 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age
NCT00759655 ·Status: TERMINATED ·Phase: PHASE3
-
Health Related Quality of Life of Youth and Young Adults With Hemophilia A
NCT01034904 ·Status: COMPLETED
-
Treatment of Hemophilia A Patients With FVIII Inhibitors
NCT04023019 ·Status: RECRUITING
-
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
NCT05568719 ·Status: RECRUITING ·Phase: PHASE3
-
Factor Product Utilization and Health Outcomes in Patients With Hemophilia
NCT02796222 ·Status: COMPLETED
-
BAX 855 Continuation
NCT01945593 ·Status: COMPLETED ·Phase: PHASE3
-
Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function
NCT02225483 ·Status: COMPLETED
-
Canadian CHO-KLAT/H-FIT Study - Quality of Life of, and Burden of Caring for, Persons With Hemophilia
NCT06191068 ·Status: COMPLETED
-
BAX 855 PK-guided Dosing
NCT02585960 ·Status: COMPLETED ·Phase: PHASE3
-
Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients
NCT02540187 ·Status: COMPLETED
-
Web Accessible Population Pharmacokinetics Service - Hemophilia: Sources of Variability
NCT03533504 ·Status: UNKNOWN
-
Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies
NCT03405337 ·Status: COMPLETED
-
Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A
NCT06579144 ·Status: RECRUITING ·Phase: PHASE1
-
A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors
NCT02571569 ·Status: COMPLETED ·Phase: PHASE1
-
Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A
NCT00717626 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A
NCT01775618 ·Status: COMPLETED ·Phase: PHASE3